Marcin Grabowski

Marcin Grabowski

Auto-generated profile, based on publicly available information

Marcin Grabowski

1st Department of Cardiology, Medical University of Warsaw, Stefana Banacha 1a, 02-097 Warsaw, Poland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2005 in JACC
Verified
Journal Article
Closed access
ZHZenon Huczek
Zenon Huczek
JKJanusz Kochman
Janusz Kochman
KFKrzysztof J. Filipiak
Krzysztof J. Filipiak
GHGrzegorz J. Horszczaruk
Grzegorz J. Horszczaruk
MGMarcin Grabowski
Marcin Grabowski
GOGrzegorz Opolski
Grzegorz Opolski

23 February 2022 in Biology
Verified
Journal Article
Open access
PDF file
MKMichał Konwerski
Michał Konwerski
Aleksandra GąseckaAleksandra Gąsecka
Aleksandra Gąsecka
GOGrzegorz Opolski
Grzegorz Opolski
MGMarcin Grabowski
Marcin Grabowski
Tomasz MazurekTomasz Mazurek
Tomasz Mazurek
Cardiovascular diseases (CVDs) are the leading causes of death worldwide. Epicardial adipose tissue (EAT) is defined as a fat depot localized between the myocardial surface and the visceral layer of the pericardium and is a type of visceral fat. EAT is one of the most important risk factors for atherosclerosis and cardiovascular events and a promising new therapeutic target in CVDs. In health conditions, EAT has a protective function, including protection against hypothermia or mechanical stress, providing myocardial energy supply from free fatty acid and release of adiponectin. In patients with obesity, metabolic syndrome, or diabetes mellitus, EAT becomes a deleterious tissue promoting the development of CVDs. Previously, we showed an adverse modulation of gene expression in pericoronary adipose tissue in patients with coronary artery disease (CAD). Here, we summarize the currently available evidence regarding the role of EAT in the development of CVDs, including CAD, heart failure, and atrial fibrillation. Due to the rapid development of the COVID-19 pandemic, we also discuss data regarding the association between EAT and the course of COVID-19. Finally, we present the potential therapeutic possibilities aiming at modifying EAT’s function. The development of novel therapies specifically targeting EAT could revolutionize the prognosis in CVDs.

1 January 2008 in Circulation Journal
Verified
Journal Article
Closed access
PDF file
Łukasz A. MałekŁukasz A. Małek
Łukasz A. Małek
BKBartlomiej Kisiel
Bartlomiej Kisiel
MSMateusz Spiewak
Mateusz Spiewak
MGMarcin Grabowski
Marcin Grabowski
KFKrzysztof J. Filipiak
Krzysztof J. Filipiak
GOGrzegorz Opolski
Grzegorz Opolski
Background Coexisting polymorphisms of the genes affecting clopiogrel resistance may influence platelet activation. Methods and Results In 105 patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention, platelet function was measured and registered as closure time in the test with collagen and adenosine diphosphate (CADP-CT). Patients were followed for 12 months for death or recurrent myocardial infarction (MI). Genotyping revealed 7 carriers of both the C allele of P2Y12 and A allele of CYP2C19 (group 1), 14 carriers of the T allele of P2Y12 and A allele of CYP2C19 (group 2), 17 carriers of the C allele of P2Y12 and G allele of CYP2C19 (group 3) and 67 carriers of the T allele of P2Y12 and G allele of CYP2C19 (controls). The median CADP-CT value was significantly lower in group 1 than in group 2 or 3 (p<0.01) or controls (p<0.002), but did not differ between group 2 or 3 and controls. There were 2 cardiovascular deaths and 4 MI during follow-up, and the median CADP-CT value was lower in these patients (p=0.09). Conclusions Coexisting, rather then single, polymorphisms of different genes may be related to persistent platelet activation while on clopidogrel, which raises concern about harm in patients with ACS. (Circ J 2008; 72: 1165 - 1169)

17 June 2023 in Biology
Verified
Journal Article
Open access
PDF file
EBEmil Brociek
Emil Brociek
ATAgata Tymińska
Agata Tymińska
AGAndrea Silvio Giordani
Andrea Silvio Giordani
Alida CaforioAlida Caforio
Alida Caforio
RWRomuald Wojnicz
Romuald Wojnicz
Krzysztof OzierańskiKrzysztof Ozierański
Krzysztof Ozierański
Myocarditis is an inflammatory disease of the myocardium caused by infectious or non-infectious agents. It can lead to serious short-term and long-term sequalae, such as sudden cardiac death or dilated cardiomyopathy. Due to its heterogenous clinical presentation and disease course, challenging diagnosis and limited evidence for prognostic stratification, myocarditis poses a great challenge to clinicians. As it stands, the pathogenesis and etiology of myocarditis is only partially understood. Moreover, the impact of certain clinical features on risk assessment, patient outcomes and treatment options is not entirely clear. Such data, however, are essential in order to personalize patient care and implement novel therapeutic strategies. In this review, we discuss the possible etiologies of myocarditis, outline the key processes governing its pathogenesis and summarize best available evidence regarding patient outcomes and state-of-the-art therapeutic approaches.

30 December 2015 in Cardiology Journal
Verified
Journal Article
Open access
PDF file
MPMichał Peller
Michał Peller
Krzysztof OzierańskiKrzysztof Ozierański
Krzysztof Ozierański
PBPawel Balsam
Pawel Balsam
MGMarcin Grabowski
Marcin Grabowski
KFKrzysztof J. Filipiak
Krzysztof J. Filipiak
GOGrzegorz Opolski
Grzegorz Opolski
Background: Endothelial dysfunction (ED) frequently precedes cardiovascular diseases (CVD) and is a well-established risk factor of major adverse cardiac events. Beta-blockers are the fundamental drugs used in CVD treatment. Methods: A systematic literature search for randomized controlled trials investigating influence of beta-blockers on endothelial function assessed by flow-mediated dilation (FMD) was performed in the PubMed and Cochrane Databases. Results: Sixteen full-text studies involving a total of 1,273 patients were included in the final analysis. The mean age of participating patients ranged from 44.9 to 63.2 years, the follow-up duration from 1 to 12 months. The comparison of FMD change between the beta-blockers and placebo groups showed a statistically significant effect of beta-blockers on endothelial function (mean difference [MD] 0.83; 95% confidence interval [CI] 0.11–1.55; p = 0.02). Third generation beta-blockers improved FMD in a statistically significant manner compared with second generation beta-blockers (MD 1.65; 95% CI 0.17–3.11; p = 0.03). Beta-blockers gave an FMD change similar to that obtained with angiotensin receptor blockers (ARB), calcium channel blockers (CCB) or hydrochlorothiazide. The FMD value in the beta-blocker group was significantly lower compared with the group treated with angiotensin converting enzyme inhibitors (ACEI) (MD –0.79; 95% CI –1.37–(–0.21); p = 0.008) and higher than in the ivabradine group (1.6 ± 3.61 vs –0.3 ± 1.66; p = 0.02). Conclusions: Beta-blockers improve the endothelial function compared with placebo. More­over, third generation beta-blockers improve FMD values significantly better than the second generation ones. Beta-blockers had similar effect on endothelial function as did ARB, CCB or diuretics. However, the beneficial effect of beta-blockers was lower when confronted with ACEI. Background: Endothelial dysfunction (ED) frequently precedes cardiovascular diseases (CVD) and is a well-established risk factor of major adverse cardiac events. Beta-blockers are the fundamental drugs used in CVD treatment. Methods: A systematic literature search for randomized controlled trials investigating influence of beta-blockers on endothelial function assessed by flow-mediated dilation (FMD) was performed in the PubMed and Cochrane Databases. Results: Sixteen full-text studies involving a total of 1,273 patients were included in the final analysis. The mean age of participating patients ranged from 44.9 to 63.2 years, the follow-up duration from 1 to 12 months. The comparison of FMD change between the beta-blockers and placebo groups showed a statistically significant effect of beta-blockers on endothelial function (mean difference [MD] 0.83; 95% confidence interval [CI] 0.11–1.55; p = 0.02). Third generation beta-blockers improved FMD in a statistically significant manner compared with second generation beta-blockers (MD 1.65; 95% CI 0.17–3.11; p = 0.03). Beta-blockers gave an FMD change similar to that obtained with angiotensin receptor blockers (ARB), calcium channel blockers (CCB) or hydrochlorothiazide. The FMD value in the beta-blocker group was significantly lower compared with the group treated with angiotensin converting enzyme inhibitors (ACEI) (MD –0.79; 95% CI –1.37–(–0.21); p = 0.008) and higher than in the ivabradine group (1.6 ± 3.61 vs –0.3 ± 1.66; p = 0.02). Conclusions: Beta-blockers improve the endothelial function compared with placebo. More­over, third generation beta-blockers improve FMD values significantly better than the second generation ones. Beta-blockers had similar effect on endothelial function as did ARB, CCB or diuretics. However, the beneficial effect of beta-blockers was lower when confronted with ACEI.

1 October 2004 in American Heart Journal
Verified
Journal Article
Closed access
MGMarcin Grabowski
Marcin Grabowski
KFKrzysztof J. Filipiak
Krzysztof J. Filipiak
GKGrzegorz Karpinski
Grzegorz Karpinski
DWDominik Wretowski
Dominik Wretowski
ARAdam Rdzanek
Adam Rdzanek
GOGrzegorz Opolski
Grzegorz Opolski